Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTI-0102 in Adults and Children With Leigh Syndrome Spectrum
NCT06990984Phase 2Not yet recruiting
- Sponsor
- Thiogenesis Therapeutics
- Start
- Oct 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of cysteamine-pantetheine disulfide in Leigh syndrome, sponsored by Thiogenesis Therapeutics. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
cysteamine-pantetheine disulfide
03
Conditions
Leigh syndrome
Beyond the preview
Go deeper on NCT06990984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06990984.